The HIV-1 treatment market for naïve and experienced patients is evolving consistently. Some of the major changes include the preference of single-tablet regimens (STRs) over multiple tablet regimens (MTRs), tenofovir alafenamide (TAF)-based therapies over tenofovir disoproxil fumarate (TDF)-based therapies, integrase strand transfer inhibitors (INSTIs) overs other classes of drugs, and approval of Cabenuva (Vocabria + Rekambys), marking a beginning of the new era of long-acting therapies.
HIV was first reported in 1981. Six years later, in March 1987, the US FDA approved zidovudine (azidothymidine), the first drug for the treatment of AIDS. Since then, the treatme...
